MedTrace Logo

Durvalumab and Oleclumab in Resectable PDAC

NCT06060405 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2024-01-08

No results posted yet for this study

Summary

This is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.

Conditions

Interventions

DRUG

Durvalumab

Durvalumab is a monoclonal antibody that blocks the interaction of PD-L1 with PD-1 on immune cells.

DRUG

Oleclumab

Oleclumab is a monoclonal antibody that binds to and inhibits the activity of CD73.

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Malcolm Moore, MD · Princess Margaret Cancer Centre/University Health Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-29
Primary Completion
2026-10-30
Completion
2026-10-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06060405 on ClinicalTrials.gov